{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:56:45Z","timestamp":1764172605296,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007834","name":"Ningbo Natural Science Foundation","doi-asserted-by":"crossref","award":["2022J039","2022J039","2022J039","2022J039","2022J039","2022J039","2022J039","2022J039"],"award-info":[{"award-number":["2022J039","2022J039","2022J039","2022J039","2022J039","2022J039","2022J039","2022J039"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Medical and Health Research Project of Zhejiang","award":["2022KY343","2022KY343","2022KY343","2022KY343","2022KY343","2022KY343","2022KY343","2022KY343"],"award-info":[{"award-number":["2022KY343","2022KY343","2022KY343","2022KY343","2022KY343","2022KY343","2022KY343","2022KY343"]}]},{"name":"The Science and Technology Project of Yinzhou","award":["2022AS069","2022AS069","2022AS069","2022AS069","2022AS069","2022AS069"],"award-info":[{"award-number":["2022AS069","2022AS069","2022AS069","2022AS069","2022AS069","2022AS069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00520-024-08344-2","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T08:03:09Z","timestamp":1706688189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The cardiac-related adverse events of PD-1\/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis"],"prefix":"10.1007","volume":"32","author":[{"given":"Bangsheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiale","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"issue":"10299","key":"8344_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA et al (2021) Lung cancer. Lancet 398(10299):535\u2013554","journal-title":"Lancet"},{"issue":"3","key":"8344_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"8344_CR3","doi-asserted-by":"crossref","unstructured":"Lahiri A et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises.\u00a0Mol Cancer\u00a022(1):40","DOI":"10.1186\/s12943-023-01740-y"},{"issue":"20","key":"8344_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ et al (2017) Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med 377(20):1919\u20131929","journal-title":"N Engl J Med"},{"issue":"3","key":"8344_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC et al (2020) Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(3):387\u2013397","journal-title":"Lancet Oncol"},{"issue":"8","key":"8344_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R et al (2020) Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol 15(8):1351\u20131360","journal-title":"J Thorac Oncol"},{"issue":"4","key":"8344_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio M et al (2021) Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol 16(4):653\u2013664","journal-title":"J Thorac Oncol"},{"issue":"12","key":"8344_CR8","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.20.02212","volume":"39","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko TK et al (2021) Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol 39(12):1349\u20131359","journal-title":"J Clin Oncol"},{"issue":"10212","key":"8344_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L et al (2019) Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929\u20131939","journal-title":"Lancet"},{"issue":"21","key":"8344_CR10","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM et al (2020) Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 38(21):2369\u20132379","journal-title":"J Clin Oncol"},{"issue":"24","key":"8344_CR11","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301","journal-title":"N Engl J Med"},{"issue":"9","key":"8344_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","volume":"32","author":"S Sugawara","year":"2021","unstructured":"Sugawara S et al (2021) Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol 32(9):1137\u20131147","journal-title":"Ann Oncol"},{"issue":"7","key":"8344_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(7):924\u2013937","journal-title":"Lancet Oncol"},{"issue":"10","key":"8344_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol 15(10):1636\u20131646","journal-title":"J Thorac Oncol"},{"issue":"9","key":"8344_CR15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C et al (2021) Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol 16(9):1501\u20131511","journal-title":"J Thorac Oncol"},{"key":"8344_CR16","doi-asserted-by":"crossref","unstructured":"Zhou YW et al (2019) Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. Front Pharmacol 10:1350","DOI":"10.3389\/fphar.2019.01350"},{"issue":"18","key":"8344_CR17","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749\u20131755","journal-title":"N Engl J Med"},{"issue":"11","key":"8344_CR18","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik AH et al (2021) Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res 128(11):1780\u20131801","journal-title":"Circ Res"},{"issue":"16","key":"8344_CR19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755\u20131764","journal-title":"J Am Coll Cardiol"},{"key":"8344_CR20","doi-asserted-by":"crossref","unstructured":"Heinzerling L et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer\u00a04:50","DOI":"10.1186\/s40425-016-0152-y"},{"key":"8344_CR21","doi-asserted-by":"crossref","unstructured":"Cham J, Ng D, Nicholson L (2021) Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.\u00a0J Med Case Reports\u00a015(1):278","DOI":"10.1186\/s13256-021-02858-7"},{"issue":"9","key":"8344_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2169\/internalmedicine.0505-22","volume":"62","author":"T Nishimura","year":"2023","unstructured":"Nishimura T et al (2023) Fulminant myocarditis for non-small-cell carcinoma of the lung with nivolumab and ipilimumab plus chemotherapy. Intern Med 62(9):1319\u20131322","journal-title":"Intern Med"},{"key":"8344_CR23","doi-asserted-by":"crossref","unstructured":"S\u0142awi\u0144ski G et al (2020) Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: a review. Int J Mol Sci 21(19):7195","DOI":"10.3390\/ijms21197195"},{"key":"8344_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/428638","volume":"2015","author":"S Yun","year":"2015","unstructured":"Yun S et al (2015) Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med 2015:1\u20135","journal-title":"Case Rep Oncol Med"},{"key":"8344_CR25","doi-asserted-by":"crossref","unstructured":"Gan L et al (2022) Cardiotoxicity associated with immune checkpoint inhibitors: current status and future challenges. Front Pharmacol 13:962596","DOI":"10.3389\/fphar.2022.962596"},{"issue":"21","key":"8344_CR26","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.2169\/internalmedicine.0255-17","volume":"57","author":"Y Katsume","year":"2018","unstructured":"Katsume Y et al (2018) Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med 57(21):3157\u20133162","journal-title":"Intern Med"},{"key":"8344_CR27","doi-asserted-by":"crossref","unstructured":"L\u00e4ubli H et al (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11","DOI":"10.1186\/s40425-015-0057-1"},{"key":"8344_CR28","doi-asserted-by":"crossref","unstructured":"Wu T et al (2023) Case report: replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma. Front Immunol 14:1243980","DOI":"10.3389\/fimmu.2023.1243980"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08344-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08344-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08344-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T08:12:00Z","timestamp":1707725520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08344-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["8344"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08344-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (this paper was provided based on researching in global databases).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}